Significance of the biopharmaceutical properties of tramadol sustained-release formulations for chrono-pharmacologically optimized treatment of pain from various sources

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 6, 2009, Pages 405-412

  Wamke, Andre ^a   Schug, B ^a   Vanderbist, F ^b   Blume, H ^a  

^a SocraTec R and D GmbH   (Germany)

^b SMB SA   (Belgium)

Author keywords

Bioavailability; Chrono pharmacokinetics; Circadian; Clinical trails; Humans; Pharmacokinetics; Sustained release; Tramadol

Indexed keywords

T LONG; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NEUROTOXICITY; NORMAL HUMAN; PAIN; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 67649964373     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47405     Document Type: Article

References (12)

1. Borlak J, Hermann R, Erb K, Thum T. Arapid and simple CYP2D6 genotyping assay - Case study with the analgetic tramadol. Metabolism. 2003; 11: 1439-1443.
2. Jackson KC. Pharmacotherapy of neuropathic pain. Pain Pract. 2006; 6: 27-33.
3. Klotz U. Tramadol - the impact of its pharmacokinetic and pharmacodynamic properties on the clinical management of pain. Arzneimittelforschung. 2003; 10: 681-687.
4. Kowanko IC, Pownall R, Knapp MS et al. Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of the day. Brit J Clin Pharmacol. 1981; 11: 477-484.
5. Lemmer B. Chronopharmacological aspects of PK/PD modelling. Int J Clin Pharmacol Ther. 1997; 10: 458-464.
6. Lemmer B. Relevance for Chronopharmacology in Practical Medicine. Seminars in Perinatology. 2000; 24: 280-290.
7. Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E. Bio-availability of enteral tramadol formulations. 1st communication: capsules. Arzneimittelforschung. 1986; 36: 1278-1283.
8. Lui XP, Song JG. Chrnopharmacology of tramadol in mice. Yao Xue Xue Bao. 2001; 36: 561-564 (Abstract; Article in Chinese).
9. Malonne H, Sonet B, Streel B, Lebrun S, De Niet S, Sereno A, Vanderbist F. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. Brit J Clin Pharmacol.. 2003; 57: 270-278.
10. Raffa RB. Anovel approach to the pharmacology of analgesics. Am J Med. 1996; 101: 40S-46S.
11. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, Jacoby HI, Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther. 1993; 267: 331-340.
12. Vener KJ, Reddy A. Timed treatment of arthritic Diseases: A Review and Hypothesis. Seminars in Arthritis and rheumatism. 1992; 2: 83-97.